Skip to main content
BICYCLE THERAPEUTICS PLC logo

BICYCLE THERAPEUTICS PLC — Investor Relations & Filings

Ticker · BCYC ISIN · US0887861088 LEI · 213800XKUI6R7GKC3E43 US Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2020-01-06 Director's Dealing
Country GB United Kingdom
Listing US BCYC

About BICYCLE THERAPEUTICS PLC

https://www.bicycletherapeutics.com/

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines known as Bicycle® molecules. These are fully synthetic bicyclic peptides engineered to combine the targeting specificity and pharmacological properties of large molecule biologics with the rapid and deep tissue penetration of small molecules. The company's proprietary platform creates precision-guided therapeutics to address diseases underserved by existing treatments. The primary focus of its development pipeline is in oncology, with a portfolio of candidates designed to target solid tumors. Beyond oncology, Bicycle Therapeutics leverages its technology through collaborations to explore applications in other therapeutic areas, including anti-infectives, cardiovascular diseases, and central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-01-06 English
FORM 4 SUBMISSION
Director's Dealing
2020-01-06 English
FORM 4/A SUBMISSION
Director's Dealing
2020-01-06 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 17, 2019, by Bicycle Therapeutics plc. The content focuses on amendments to the company's Non-Employee Director Compensation Policy, including changes to stock option grants and compensation for committee chairs. The key section is Item 5.02, which relates to the departure, election, or appointment of directors or officers and their compensatory arrangements. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document announces changes in board compensation and director-related policies, which fits the category of Board/Management Information (MANG). The document length is about 5,131 characters, which is sufficient for a substantive announcement rather than a brief notice. Therefore, the appropriate classification is MANG with high confidence.
2019-12-23 English
FORM 4 SUBMISSION
Director's Dealing
2019-12-20 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 20, 2019. It reports the posting of an updated corporate presentation on the company's website, describing expected key events in 2020, including clinical trial initiations and data updates. The document explicitly states that the presentation is furnished as Exhibit 99.1 and is incorporated by reference. The text does not contain detailed financial statements or substantive financial data but rather announces the availability of a presentation. The document length is 4428 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the presentation), not the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2019-11-20 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.